Switch theme
Sign up to access all valuation multiples
Philogen SpA is a biotechnology company. The company develops biotech products for the imaging and therapy of life-threatening diseases. The company's focus is predominantly related to oncology drug development, although the company has also brought products for the treatment of chronic inflammatory diseases to the clinic. Its pipeline products include Nidlegy; Fibromun; Darleukin; Dodekin; Dekavil and others. Geographically, the company operates in the European Union, Switzerland, and the United States of America.
1996
183
LTM Revenue $254M
LTM EBITDA $203M
$951M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Philogen has a last 12-month revenue (LTM) of $254M and a last 12-month EBITDA of $203M.
In the most recent fiscal year, Philogen achieved revenue of $87.2M and an EBITDA of $52.8M.
Philogen expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Philogen valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $254M | XXX | $87.2M | XXX | XXX | XXX |
| Gross Profit | $248M | XXX | $64.1M | XXX | XXX | XXX |
| Gross Margin | 98% | XXX | 74% | XXX | XXX | XXX |
| EBITDA | $203M | XXX | $52.8M | XXX | XXX | XXX |
| EBITDA Margin | 80% | XXX | 61% | XXX | XXX | XXX |
| EBIT | $199M | XXX | $45.1M | XXX | XXX | XXX |
| EBIT Margin | 78% | XXX | 52% | XXX | XXX | XXX |
| Net Profit | $175M | XXX | $53.4M | XXX | XXX | XXX |
| Net Margin | 69% | XXX | 61% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 18, 2025, Philogen's stock price is EUR 23 (or $27).
Philogen has current market cap of EUR 910M (or $1.1B), and EV of EUR 807M (or $951M).
See Philogen trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $951M | $1.1B | XXX | XXX | XXX | XXX | $4.32 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 18, 2025, Philogen has market cap of $1.1B and EV of $951M.
Philogen's trades at 10.9x EV/Revenue multiple, and 18.0x EV/EBITDA.
Equity research analysts estimate Philogen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Philogen has a P/E ratio of 6.1x.
See valuation multiples for Philogen and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EV (current) | $951M | XXX | $951M | XXX | XXX | XXX |
| EV/Revenue | 3.7x | XXX | 10.9x | XXX | XXX | XXX |
| EV/EBITDA | 4.7x | XXX | 18.0x | XXX | XXX | XXX |
| EV/EBIT | 4.8x | XXX | 21.1x | XXX | XXX | XXX |
| EV/Gross Profit | 3.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 6.1x | XXX | 20.1x | XXX | XXX | XXX |
| EV/FCF | 6.7x | XXX | 21.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPhilogen's last 12 month revenue growth is -18%
Philogen's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.1M for the same period.
Philogen's rule of 40 is -27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Philogen's rule of X is 35% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Philogen and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -18% | XXX | -17% | XXX | XXX | XXX |
| EBITDA Margin | 80% | XXX | 61% | XXX | XXX | XXX |
| EBITDA Growth | -24% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -27% | XXX | 43% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 35% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 22% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Philogen acquired XXX companies to date.
Last acquisition by Philogen was XXXXXXXX, XXXXX XXXXX XXXXXX . Philogen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Philogen founded? | Philogen was founded in 1996. |
| Where is Philogen headquartered? | Philogen is headquartered in Italy. |
| How many employees does Philogen have? | As of today, Philogen has 183 employees. |
| Who is the CEO of Philogen? | Philogen's CEO is Professor Dario Neri, PhD. |
| Is Philogen publicy listed? | Yes, Philogen is a public company listed on MIL. |
| What is the stock symbol of Philogen? | Philogen trades under PHIL ticker. |
| When did Philogen go public? | Philogen went public in 2021. |
| Who are competitors of Philogen? | Similar companies to Philogen include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Philogen? | Philogen's current market cap is $1.1B |
| What is the current revenue of Philogen? | Philogen's last 12 months revenue is $254M. |
| What is the current revenue growth of Philogen? | Philogen revenue growth (NTM/LTM) is -18%. |
| What is the current EV/Revenue multiple of Philogen? | Current revenue multiple of Philogen is 3.7x. |
| Is Philogen profitable? | Yes, Philogen is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Philogen? | Philogen's last 12 months EBITDA is $203M. |
| What is Philogen's EBITDA margin? | Philogen's last 12 months EBITDA margin is 80%. |
| What is the current EV/EBITDA multiple of Philogen? | Current EBITDA multiple of Philogen is 4.7x. |
| What is the current FCF of Philogen? | Philogen's last 12 months FCF is $143M. |
| What is Philogen's FCF margin? | Philogen's last 12 months FCF margin is 56%. |
| What is the current EV/FCF multiple of Philogen? | Current FCF multiple of Philogen is 6.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
